Startseite The crystal structure of 2,5-bis[(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)amino]cyclohexa-2,5-diene-1,4-dione, C28H26N6O4
Artikel Open Access

The crystal structure of 2,5-bis[(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)amino]cyclohexa-2,5-diene-1,4-dione, C28H26N6O4

  • Mark G. Smith ORCID logo EMAIL logo und Andreas Lemmerer
Veröffentlicht/Copyright: 24. Januar 2024

Abstract

C28H26N6O4, monoclinic, P21/n (no. 14), a = 13.0398(4) Å, b = 7.1786(2) Å, c = 14.9824(5) Å, β = 112.642(2)°, V = 1294.37(7) Å3, Z = 2, R gt (F) = 0.0458, wR ref (F2) = 0.1133, T = 173 K.

CCDC no.: 1873547

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal: Red plate
Size: 0.27 × 0.22 × 0.05 mm
Wavelength:

μ:
Mo Kα radiation (0.71073 Å)

0.09 mm−1
Diffractometer, scan mode:

θmax, completeness:
Bruker D8 Venture Photon, ω

28.0°, >99 %
N(hkl)measuredN(hkl)uniqueRint: 13992, 3129, 0.055
Criterion for Iobs, N(hkl)gt: Iobs > 2σ(Iobs), 2084
N(param)refined: 174
Programs: Bruker [1], SHELX [2, 3], ORTEP-3 [4], WinGX [5], PLATON [6]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

Atom x y z Uiso*/Ueq
C1 0.84918 (13) 0.1380 (2) 0.18497 (12) 0.0270 (4)
C2 0.75806 (12) 0.2663 (2) 0.14884 (12) 0.0261 (4)
C3 0.79275 (13) 0.4234 (2) 0.11951 (12) 0.0298 (4)
C4 0.72905 (15) 0.5966 (3) 0.08058 (16) 0.0442 (5)
H4A 0.652278 0.580644 0.075273 0.066*
H4B 0.729433 0.622967 0.016525 0.066*
H4C 0.76339 0.700644 0.124236 0.066*
C5 0.98011 (15) 0.5597 (2) 0.15612 (15) 0.0378 (4)
H5A 0.943209 0.672252 0.121597 0.057*
H5B 1.042865 0.528893 0.138161 0.057*
H5C 1.007221 0.581582 0.225979 0.057*
C6 1.03204 (12) 0.1451 (2) 0.16911 (13) 0.0284 (4)
C7 1.09452 (13) 0.0243 (3) 0.24133 (14) 0.0376 (5)
H7 1.077947 0.006366 0.297181 0.045*
C8 1.18207 (15) −0.0706 (3) 0.23076 (17) 0.0470 (5)
H8 1.224428 −0.156435 0.279199 0.056*
C9 1.20830 (15) −0.0423 (3) 0.15143 (17) 0.0482 (5)
H9 1.269145 −0.106364 0.145522 0.058*
C10 1.14578 (15) 0.0794 (3) 0.08065 (16) 0.0447 (5)
H10 1.163957 0.099844 0.025822 0.054*
C11 1.05667 (14) 0.1724 (3) 0.08834 (14) 0.0350 (4)
H11 1.012794 0.25432 0.03847 0.042*
C12 0.58126 (12) 0.1152 (2) 0.06900 (12) 0.0245 (4)
C13 0.61111 (12) 0.0224 (2) 0.00389 (12) 0.0279 (4)
H13 0.683835 0.039001 0.004929 0.033*
C14 0.53623 (13) −0.0990 (2) −0.06586 (12) 0.0263 (4)
N1 0.64785 (10) 0.22716 (19) 0.13868 (10) 0.0279 (3)
H1 0.62223 0.277971 0.179431 0.033*
N2 0.93877 (10) 0.23537 (18) 0.17834 (10) 0.0281 (3)
N3 0.90109 (11) 0.40502 (18) 0.13017 (11) 0.0299 (3)
O1 0.85424 (9) −0.02470 (16) 0.21230 (9) 0.0372 (3)
O2 0.56117 (9) −0.19396 (17) −0.12277 (9) 0.0378 (3)

1 Source of materials

All reagents used were commercially available and used without further purification. An amount of 0.0832 g of 4-aminoantipyrine (0.409 mmol) and 0.0611 g of 2,5-dihydroxy-1,4-benzoquinone (0.408 mmol) were added into a sample vial. The solids were dissolved in 20 mL of a mixture of equal parts of 1,2-dichloroethane, methanol, chloroform, and toluene, and stirred for 120 min. Six drops of dimethylformamide were added to ensure that the solid was fully dissolved. The solution was left to stand very slightly opened to the atmosphere. Red plates were afforded after 14 days. The unusual mixture of solvents is due to the fact that initially the reagents would not dissolve in 5 mL of 1,2-dichloroethane. Therefore, 5 mL of each of the other solvents were added one by one until the reagents started dissolving.

2 Experimental details

C-bound hydrogen atoms were located in the difference map then were allowed to ride on their respective parent atoms with thermal displacement parameters 1.2 times of the parent C atom. Diagrams and publication material were generated using ORTEP-3 [4], WinGX [5] and PLATON [6].

3 Comment

4-Aminoantipyrine (4AAP) was traditionally employed as a preventative measure against oxidative stress [7] and as an antipyretic medicinal medicine [8]. Li et al. [9], as well as Mnguni et al. [10] have both published the crystal structure of 4AAP. Furthermore, a co-crystal of 4AAP has been reported by Smith and Lemmerer [11]. Two derivatives of 4AAP, namely aminoantipyrine and 4-(N,N-dimethyl)-aminoantipyrine have been used medicinally since the 19th century, and the modification of 4AAP therefore presents potential for the creation of new pharmaceutical drugs. This paper presents the crystal structure of a modification of 4AAP.

The structure crystallizes in the P21/n space group and the asymmetric unit contains one molecule. As shown in the figure, the molecule has a center of inversion and one half of the molecule is generated by symmetry. The reaction of the two hydroxy groups of 2,5-dihydroxy-1,4-benzoquinone with the amine groups of two 4AAP molecules produced the enamine structure presented in this paper. The two amine groups provide hydrogen bond donors to the antipyrine carbonyl acceptor of two different molecules to form two N–H⋯O heterosynthons. These hydrogen bonds form a C(10) chain with a screw axis down the b-axis, resulting in 1D ribbons along that axis.


Corresponding author: Mark G. Smith, Department of Chemistry, University of South Africa, Unisa Science Campus, 28 Pioneer Avenue Florida, Roodepoort, Gauteng, South Africa, E-mail:

  1. Author contributions: The author has accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: The University of the Witwatersrand and the Molecular Sciences Institute are thanked for providing the infrastructure and financial support to do this work. Mark G. Smith thanks the Chemistry Department of the University of South Africa for their financial support and Andreas Lemmerer thanks the Wits Friedel Sellschop award for funding.

References

1. Bruker. APEX2 (Version 2012.10–0), Saint (version 27B), SAINT (version 8.27B), (version 2012/1); Bruker AXS Inc: Madison, Wisconsin, USA, 2012.Suche in Google Scholar

2. Sheldrick, G. M. SHELXTL – integrated space-group and crystal-structure determination. Acta Crystallogr. 2015, A71, 3–8.10.1107/S2053273314026370Suche in Google Scholar PubMed PubMed Central

3. Sheldrick, G. M. Crystal structure refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.Suche in Google Scholar

4. Farrugia, L. J. WinGX and ORTEP for Windows: an update. J. Appl. Crystallogr. 2012, 45, 849–854; https://doi.org/10.1107/s0021889812029111.Suche in Google Scholar

5. Farrugia, L. J. WinGX suite for small-molecule single-crystal crystallography. J. Appl. Crystallogr. 1999, 32, 837–838; https://doi.org/10.1107/s0021889899006020.Suche in Google Scholar

6. Spek, A. L. Structure validation in chemical crystallography. Acta Crystallogr. 2009, D65, 148–155; https://doi.org/10.1107/s090744490804362x.Suche in Google Scholar

7. Teng, Y., Liu, R., Li, C., Zhang, H. Effect of 4-aminoantipyrine on oxidative stress induced by glutathione depletion in single human erythrocytes using a microfluidic device together with fluorescence imaging. J. Hazard. Mater. 2011, 192, 1766–1771; https://doi.org/10.1016/j.jhazmat.2011.07.012.Suche in Google Scholar PubMed

8. Acheson, R. M. An introduction to the chemistry of heterocyclic compounds. J. Pharm. Sci. 1960, 49, 739.Suche in Google Scholar

9. Li, Y., Liu, Y., Wang, H., Xiong, X., Wei, P., Li, F. Synthesis, crystal structure, vibration spectral, and DFT studies of 4-aminoantipyrine and its derivatives. Molecules 2013, 18, 877; https://doi.org/10.3390/molecules18010877.Suche in Google Scholar PubMed PubMed Central

10. Mnguni, M. J., Lemmerer, A. A structural study of 4-aminoantipyrine and six of its Schiff base derivatives. Acta Crystallogr. 2015, C71, 103–109; https://doi.org/10.1107/s2053229614027247.Suche in Google Scholar PubMed

11. Smith, M. G., Lemmerer, A. Novel crystal forms of 4-aminoantipyrine and its derivatives: Co-crystallizing a reluctant molecule. J. Mol. Struct. 2019, 1175, 307–313; https://doi.org/10.1016/j.molstruc.2018.07.062.Suche in Google Scholar

Received: 2023-11-20
Accepted: 2023-12-26
Published Online: 2024-01-24
Published in Print: 2024-04-25

© 2023 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Artikel in diesem Heft

  1. Frontmatter
  2. New Crystal Structures
  3. Solvothermal synthesis and crystal structure of aqua-tris(p-acetamidobenzoate-κ2O,O′)-(2,2′-bipyridine-κ2N,N′)terbium(III) - water - methanol (1/1/1)
  4. Crystal structure of hexaaquazinc(II) catena-poly[bis(1-(3-carboxyphenyl)-5-methyl-4-oxo-1,4-dihydropyridazine-3-carboxylato-κ2O,O′)-bis(μ2-1-(3-carboxyphenyl)-5-methyl-4-oxo-1,4-dihydropyridazine-3-carboxylato-κ2O:O′)trizinc(II)] hexahydrate C26H36N4O20Zn2
  5. The crystal structure of valinyl-N-ium-4-(5-(thiophen-2-yl)isoxazol-3-yl)phenyl trifluoroacetate
  6. Crystal structure of bis(3,5-diisopropyl-1H-pyrazol-4-ammonium) tetrafluoroterephthalate, 2[C9H18N3][C8F4O4]
  7. Crystal structure of aqua-octakis(μ3-salicylato)-(1,10-phenanthroline)-(acetonitrile)-dicobalt(II)-trititanium(IV), C70H45N3O25Co2Ti3
  8. Crystal structure of catena-poly[aqua-(μ2-4,4′-diimidazole diphenyl ether-κ2N:N′)-(sulfato-κ1O)-cobalt(II)] – dimethylformamide (2/1), C39H37CoN9O8S
  9. Crystal structure of (5R,8R,9R,10R,12R, 13R,14R,17S)-2-(E-3-fluorobenzylidene)-12-hydroxy-4,4,8,10,14-pentamethyl-17-((R)-2,6,6-trimethyltetrahydro-2H-pyran-2-yl) hexadecahydro-3H-cyclopenta[a]phenanthren-3-one, C37H53FO3
  10. Crystal structure of (Z)-4-((4,5,6-trimethoxy-3-oxobenzofuran-2(3H)-ylidene)methyl)phenyl diphenylphosphinate, C30H25O7P
  11. Crystal structure of 3-((5-methylpyridin-2-yl)amino)-1-phenylpropan-1-one, C15H16N2O
  12. The crystal structure of (R)-9-(5-methoxy-2-methyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-ylidene)-9H-thioxanthene, C28H22OS
  13. Crystal structure of diaqua-bis[1-(1-(hydroxymethyl)-1H-pyrazol-3-yl)-5-methyl-1H-1,2,3-triazole-4-carboxylato-κ2N,O)] manganese(II), C16H20MnN10O8
  14. The crystal structure of t-butyl 7-[4-(4-fluorophenyl)-2-[(methanesulfonyl)(methyl)amino]-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate, C26H36FN3O6S
  15. The crystal structure of samarium sulfate pentahydrate, Sm2(SO4)3(H2O)5
  16. The crystal structure of [triaqua-(8-carboxymethoxy-quinoline-2-carboxylate-κ 4 N,O,O,O)-zinc(II)] monohydrate, C12H15NO9Zn
  17. The crystal structure of 2,3-difluoro-11H-benzo-[4,5]imidazo[2,1-a]isoindol-11-one, C14H6F2N2O
  18. The crystal structure of 2,3-di(9H-carbazol-9-yl)-9H-fluoren-9-one, C37H22N2O
  19. The crystal structure of 5-(2-chloro-3-(3,6-di-tert-butyl-9H-carbazol-9-yl)phenyl)-10,11-dihydro-5H-dibenzo[b,f]azepine, C40H39ClN2
  20. Crystal structure of 2-bromo-1-hydroxy-3-(3-methylbut-2-enyloxy)-9H-xanthen-9-one, C18H15BrO4
  21. Crystal structure of bis(μ2-benzenesulfonato-κ2O:O′)-bis(μ2-6,6′-((ethane-1,2-diylbis(azaneylylidene))bis(methaneylylidene))-bis(2-methoxyphenolato-κ6O,O′:O′,N,N′,O′′:O′′,O′′′))disodium(I)dicopper(II)
  22. The crystal structure of (E)-1,2-bis(benzo[e][1,2]azaborinin-2(1H)-yl)ethene, C18H16B2N2
  23. Crystal structure of 3-oxo-urs-12-en-28-benzyl ester, C37H52O3
  24. The crystal structure of ethyl (E)-1-chloro-3-(4-chloro-1-methyl-1H-indole-2-carbonyl)-4-oxo-2-phenylcyclooct-2-ene-1-carboxylate, C27H25Cl2NO4
  25. The crystal structure of 4,4′-((5-bromo-2-iodo-1,3-phenylene)bis(oxy))bis(tert-butylbenzene) ─ ethanol (2/1), C26H28BrIO2
  26. Crystal structure of (E)-1-(4-(benzyloxy)-2-hydroxyphenyl)-3-(dimethylamino)prop-2-en-1-one, C18H19NO3
  27. The crystal structure of N1,N3-bis(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)\ propanediamide hydrate, C25H26N6O4, 2(H2O)
  28. The crystal structure of 2,5-bis[(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)amino]cyclohexa-2,5-diene-1,4-dione, C28H26N6O4
  29. Crystal structure of 3,4-bis[2-(hydroxymethyl)-pyrrolidin-1-yl] cyclobut-3-ene-1,2-dione hydrate, C14H22N2O5
  30. The crystal structure of 2-(3,4–dichlorobenzyl)-1H-benzimidazole, C14H10Cl2N2
  31. The crystal structure of 2-(2-((4,6-dimethoxypyrimidin-2-yl)oxy)phenyl)-4-(piperidin-1-yl)-5H-chromeno[2,3-d]pyrimidine, C28H27N5O4
  32. The crystal structure of 6-(benzofuran-2-yl)-2-oxo-4,5-diphenyl-3,4-dihydro-2H-pyran-3-carbonitrile, C26H17NO3
  33. Crystal structure of N-(4-bromobenzyl)-3-(difluoromethyl)-1-methyl-N-(pyridin-2-yl)-1H-pyrazole-4-carboxamide, C18H15BrF2N4O
  34. The crystal structure of the host-guest complex: N-{5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl}-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide-diethyl ether (2/1)
  35. The crystal structure of (Z)-4-amino-N-(1-(4-hydroxyphenyl)propylidene)benzohydrazide, C16H17N3O2
  36. The crystal structure of diethyl 1,4-dihydro-2,6-dimethyl-4-(3-cyanophenyl)-3,5-pyridinedicarboxylate, C20H22N2O4
  37. Crystal structure of 3-(5-((4-(difluoromethoxy)phenyl) sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl) oxetane-3-carboxamide, C17H19F2N3O5S
  38. Crystal structure of 2-((2,6-dichloro-4-(3,5-dimethylisoxazol-4-yl)phenyl)amino)-N-(2-(4-methylpiperazin-1-yl)ethyl)benzamide hydrate, C25H37Cl2N5O6
  39. Crystal structure of 3-(benzo[d]thiazol-2-yl)-5-bromo-2-hydroxybenzaldehyde, C14H8BrNO2S
  40. Crystal structure of 3-(difluoromethyl)-1-methyl-N-(pyridin-2-yl)-1H-pyrazole-4-carboxamide, C11H10F2N4O
  41. Crystal structure of 3-(2-ethoxy-2-oxoethyl)-1-isopropyl-1H-imidazol-3-ium hexafluoridophosphate(V), C20H34F12N4P2
  42. Crystal structure of ethyl 5,6-dichloro-2-methyl-2,3-dihydro-1 H-benzo[d]imidazole-2-carboxylate, C11H12Cl2N2O2
  43. The crystal of structure of (OC-6-22)-pentakis(acetonitrile)bromidoruthenium(II)bromide monohydrate, C10H15Br2N5Ru
  44. Crystal structure of (2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-(((4aS,5R,6S)-1-oxo-5-vinyl-4,4a,5,6-tetrahydro-1H,3H-pyrano[3,4-c]pyran-6-yl)oxy)tetrahydro-2H-pyran-3-yl 2,3-dihydroxybenzoate hydrate, C23H26O12·H2O
  45. The crystal structure of (E)-4-amino-N′-(1-(4-fluorophenyl)propylidene)benzohydrazide, C16H16FN3O
  46. The crystal structure of 2′-(9H-carbazol-9-yl)-[1,1′-binaphthalen]-2-amine, C32H22N2
  47. Crystal structure of poly[μ3-diiodido-[μ2-di(1H-pyrazol-1-yl)methane-κ2N,N′)]dicopper(I)], C7H8Cu2I2N4
  48. Crystal structure of 3-amino-N′-hydroxy-1H-pyrazole-4-carboximidamide, C4H7N5O
  49. The crystal structure of 1,3-diacetyltetrahydroimidazo[4,5-d]imidazole-2,5(1H,3H)-dione, C8H10O4N4
  50. Crystal structure of catena-poly[aqua-(μ2-1,4-diazabicyclo[2.2.2]octane-k2N: N′)-bis(sorbato-κ1O)-copper(II), C18H28CuN2O5
  51. Crystal structure of catena-poly[triaqua-(μ2 -1-(4-carboxylatophenyl)-4-oxo-1,4-dihydropyridazine-3-carboxylato-κ3O,O′:O′′)manganese(II)], C12H12N2O8Mn
  52. The crystal structure of [hexaaquamagnesium(II)] 4-[(pyridine-4-carbonyl)-amino]-phthalate trihydrate, C14H26N2O14Mg
  53. Crystal structure of 1-(p-tolylphenyl)-4-(2-furoyl)-3-methyl-1H-pyrazol-5-ol, C16H14N2O3
  54. The crystal structure of bis(1,4,7,10,13-pentaoxacyclopentadecane)-potassium(I) dichloridocopper(I), C20H40Cl2CuKO10
  55. The crystal structure of tris(tetra-n-butylammonium) hexanitrato-κ2O,O′-lanthanium(III) C48H108N9O18La
Heruntergeladen am 20.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2023-0508/html?lang=de
Button zum nach oben scrollen